Optimisation of pathogenetic therapy of acute intestinal infections in children: results of a randomised trial

Руженцова, Т. А.; Плоскирева, А.А.; Попова, Раиса; Nuribekov, S.A.; Gorelov, А.V.

doi:10.20953/1729-9225-2018-2-70-76

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are consistent with previously published data from three studies of acute intestinal infection in children 8–10. Diarrhoea resolved more rapidly in patients treated with Enterosgel compared with standard care8 or antibiotic and standard care 9.…”

Section: Discussionsupporting

confidence: 92%

“…A meta-analysis found that diosmectite, a natural clay intestinal adsorbent, significantly decreased the duration of acute diarrhoea in comparison with placebo, although further studies were recommended 7. Several studies have suggested that Enterosgel, an intestinal adsorbent consisting of an organosilicon compound, polymethylsiloxane polyhydrate, could be effective in the treatment of gastrointestinal disorders 8–12…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial

Howell

Markaryan

Allgar

et al. 2019

BMJ Open Gastroenterol

View full text Add to dashboard Cite

BackgroundAcute intestinal infections are common conditions causing high morbidity and mortality especially in the young and elderly, resulting in a significant burden on health service resources and the economy. Current National Institute for Health and Care Excellence guidance are fluid and nutritional management; however, this does not reduce the duration of diarrhoea and the challenge of treating diarrhoea itself remains. We investigated the efficacy, tolerability and safety of intestinal adsorbent Enterosgel (polymethylsiloxane polyhydrate) compared with standard care in adults with acute diarrhoea.MethodsThis was a randomised controlled trial enrolling 105 subjects to receive the medical device Enterosgel up to six times daily for up to 8 days with standard care (oral rehydration solution), or standard care alone. The primary endpoint was the duration of diarrhoea (hours) from randomisation to first non-loose stool in the Enterosgel versus control group.ResultsA total of 51 subjects were randomised into the Enterosgel group and 54 into the control group, after excluding missing data, the data from 43 subjects in each group were analysed. Duration of diarrhoea was significantly shorter in the Enterosgel group at 27 hours versus 39 hours in the control group (HR was 1.74 [95% CI 1.06 to 2.87]) (p=0.03). This yielded a number needed to treat value of 5. Enterosgel was well tolerated and safe with no serious adverse events. One serious diarrhoea-related event resulting in hospitalisation was reported in the control group.ConclusionsEnterosgel treatment was associated with a significant reduction in the duration of diarrhoea in adults with patient-reported acute diarrhoea, compared with standard care. These findings support the role of Enterosgel in acute diarrhoea especially in vulnerable groups where rapid resolution of symptoms is required. Reduction in symptom duration could translate to less healthcare costs and socioeconomic burden.Trial registration numberISRCTN20758708

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial

Howell

Markaryan

Allgar

et al. 2019

BMJ Open Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Detailed characteristics of the included RCTs are presented in Table 1. We excluded one trial due to reported co-intervention and comparison with a different probiotic [17]. Four RCTs that randomized 347 participants (172 in the experimental group and 175 in the control group) who ranged in age from 3 months to 5 years were identified [7,8,9,12].…”

Section: Resultsmentioning

confidence: 99%

Systematic Review with Meta-Analysis: Lactobacillus reuteri DSM 17938 for Treating Acute Gastroenteritis in Children. An Update

Patro-Gołąb

Szajewska

2019

Nutrients

View full text Add to dashboard Cite

The effectiveness of Lactobacillus reuteri DSM 17938 (L. reuteri) for the management of acute gastroenteritis (AGE) has been recently questioned. We performed a systematic review to update evidence on L. reuteri for treating AGE in children. We searched MEDLINE, EMBASE, the Cochrane Library databases, and additional data sources from January 2016 (end of search for our 2016 systematic review) to August 2019. The primary outcomes were stool volume and duration of diarrhea. Four RCTs were included. None of them evaluated stool volume. Compared with placebo or no treatment, L. reuteri reduced diarrhea duration (four RCTs, n = 347, mean difference, MD −0.87 days, 95% CI [−1.43, −0.31]). L. reuteri use was also associated with a reduced duration of hospitalization (three RCTs, n = 284, MD −0.54 days, 95% CI [−1.09, 0.0]). The small effect sizes of limited clinical relevance and methodological limitations of the included trials should be noted when interpreting these findings.

show abstract

“…положительный ответ на терапию был достаточно быстрый, коррекции схемы в большинстве случаев не требовалось. однако, в отличие от изученных нами ранее инфекционных диарей, продолжительность диареи при COVID-19 была дольше, меньше выражен результат в ответ на начало лечения [4]. после купирования диареи нередко сохранялись плохой аппетит, тошнота, дискомфорт после еды, метеоризм, что становилось поводом для назначения препаратов на основе ферментов.…”

Section: результаты и обсуждениеunclassified

Gastrointestinal Tract Disorders in COVID-19 Infected Children

Попова

Руженцова

Хавкина

et al. 2020

Problemy Osobo Opasnykh Infektsii

View full text Add to dashboard Cite

Objective of the work was to investigate the peculiarities of gastrointestinal tract disorders in children with coronavirus disease caused by SARS-CoV-2 virus.Materials and methods. We have analyzed the frequency, terms of emergence, duration and character of gastrointestinal disorders on the basis of medical records of 36 children receiving the treatment for community-acquired pneumonia of coronavirus etiology (positive for SARS-CoV-2 virus) in the children’s infectious disease department of Moscow State Clinical Hospital, Mytishchi. The majority of patients had moderate form of the disease (97 %), severe cases were not registered. The age range of the children – 8 months to17 years old. All patients were subjected to supplementary examination on Day 1 in accordance with the current recommendations. Children were treated in hospital settings for 8–15 days. Assessment of clinical status was performed at least once a day over the stated period, supplementary survey – at least once in a week, upon indications – more frequently. SARSCoV-2 virus was identified using polymerase chain reaction. All patients received standard therapy in compliance with advanced methodological recommendations, upon indications – other pharmaceutical products.Results and discussion. Gastro-intestinal disorders in 23 children (64 %) emerged on Day 4–5, in 8 children (22 %) – before the start of the treatment; they lasted 3–5 days. In most of the patients diarrhea (64 %) and stomachaches (57 %) were observed. 67 % of the children demonstrated other symptoms indicative of gastrointestinal dysfunction. The disorders were characteristic for most of the children hospitalized with community-acquired pneumonia caused by SARS-CoV-2 virus. The symptoms are contained when the main course of therapy is conducted, indicated for treatment of COVID-19, and additional therapy recommended for management of gastro-intestinal infections is performed.

show abstract

Optimisation of pathogenetic therapy of acute intestinal infections in children: results of a randomised trial

Cited by 4 publications

References 0 publications

Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial

Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial

Systematic Review with Meta-Analysis: Lactobacillus reuteri DSM 17938 for Treating Acute Gastroenteritis in Children. An Update

Gastrointestinal Tract Disorders in COVID-19 Infected Children

Contact Info

Product

Resources

About